INFU vs UNH

INFU exhibits strong operational health with a Piotroski F-Score of 8/9, indicating significant improvements in financial efficiency and stability. However, the stock is currently trading at a premium to both its Graham Number ($4.45) and Intrinsic Value ($9.14), following a massive 106% one-year price surge. While earnings growth is explosive (123.9% YoY), the technical trend is severely bearish (10/100), suggesting a potential peak or correction phase. The investment thesis is tempered by a heavy reliance on third-party healthcare reimbursements, which introduces systemic regulatory risk.

UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.